Tesaro announces nine data presentations at ESMO meeting
TESARO announced that data from nine abstracts will be presented at the 2017 European Society for Medical Oncology annual meeting, September 8 to September 12, 2017, in Madrid. "We are excited that a wealth of data from the landmark ENGOT-OV16/NOVA trial will be presented at this year's ESMO Annual Meeting," said Mary Lynne Hedley, Ph.D., President and COO of TESARO. "Patient-reported quality of life data for patients treated with niraparib versus placebo will be featured in an oral presentation and the results of two post-hoc analyses, the observed exposure-response relationship of niraparib in gBRCAmut and non-gBRCAmut patients, and the safety and efficacy of niraparib in elderly patients, will be subjects for poster discussions. In addition, data from the Phase 1/2 trial of niraparib plus pembrolizumab in patients with triple-negative breast cancer or recurrent platinum-resistant ovarian cancer will be highlighted in a poster discussion. Finally, a poster will be presented detailing results from the Phase 1 study of TSR-042, our anti-PD-1 antibody."